___

• 1. Malluche HH. Renal bone disease--an ongoing challenge to the nephrologist. Clin Nephrol 1995; 44 (Suppl 1): S38-41
• 2. Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int (Suppl) 1992; 38: S62-7
• 3. Monier-Faugere MC, Malluche HH. Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transplant 1996; 11 (Suppl 3): 111-20
• 4. Coen G, Mazzaferro S. Bone metabolism and its assessment in renal failure. Nephron 1994; 67: 383-401
• 5. Hutchison AJ, Whitehouse RW, Boulton HF ve ark. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 1993; 44: 1071-7
• 6. Couttenye MM, D'Haese PC, Verschoren WJ ve ark. Low bone turnover in patients with renal failure. Kidney Int (Suppl) 1999; 73: S70-6
• 7. Couttenye MM, D'Haese PC, Van Hoof VO ve ark. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1065-72
• 8. Morishita T, Nomura M, Hanaoka M ve ark. A new assay method that detects only intact osteocalcin. Two-step non-invasive diagnosis to predict adynamic bone disease in haemodialysed patients. Nephrol Dial Transplant 2000; 15: 659-67
• 9. Torres A, Lorenzo V, Hernandez D ve ark. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995; 47: 1434- 42
• 10. Hruska KA, Teitelbaum SL: Renal osteodystrophy. N Engl J Med 1995; 333: 166-74
• 11. Hercz G, Pei Y, Greenwood C ve ark. Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. Kidney Int 1993; 44: 860-6
• 12. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993; 4: 1205-13
• 13. Akizawa T, Kinugasa E, Akiba T ve ark. Incidence and clinical characteristics of hypoparathyroidism in dialysis patients. Kidney Int Suppl 1997; 62: S72-4
• 14. Avram MM, Sreedhara R, Avram DK ve ark. Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia. Am J Kidney Dis 1996; 28: 924-30
• 15. Navarro JF, Mora C, Jimenez A ve ark. Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients. Am J Kidney Dis 1999; 34: 43-8
• 16. Guh JY, Chen HC, Chuang HY ve ark. Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am J Kidney Dis 2002; 39: 1245-54
• 17. Niikura K, Akizawa T, Satoh Y ve ark. Relative hypoparathyroidism in hemodialysis patients. Miner Electrolyte Metab 1995; 21: 101-3
• 18. Pei Y, Hercz G, Greenwood C ve ark. Renal osteodystrophy in diabetic patients. Kidney Int 1993; 44: 159-64
• 19. Couttenye MM, D'Haese PC, Deng JT ve ark. High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol Dial Transplant 1997; 12: 2144-50